Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, r00kie, joboggi, Sir Francelote, zoomboom, Rosym
Search This Board:
Last Post: 10/23/2014 10:53:11 AM - Followers: 717 - Board type: Free - Posts Today: 3

   

Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia. The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard"). For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+



            

 
PRESS RELEASES & NEWS ARTICLES

Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Oct 20, 2014 8:01 a.m.
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) Developer of LymPro on Watch Here!
OCTOBER 16, 2014
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 

Oct 16, 2014   9:30 a.m.
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 9, 2014    6:01 a.m.
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct 7, 2014    8:01 a.m.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies
Oct 1, 2014    9:16 p.m.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept 29, 2014     2:04 p.m.
Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
Sept 25, 2014     4:00 p.m.
Amarantus on road to commercializing AD test
September 23, 2014
Fundamental Milestones Ahead: Up-Listing from Strength
Thrursday, Sept. 18th 2014   12:30 p.m.
Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Sept 17, 2014    8:00 a.m.
Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
Sept 12, 2014   10:30 a.m.
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
Sept 10, 2014   1:00 p.m.
Amarantus Announces Positive MANF Ocular Toxicology Data
Sept. 9, 2014   8:31 a.m.
Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Sept 4, 2014   9:00 a.m.
Initiating Studies for CLIA Launch at Icon Central Laboratories
September 2nd, 2014   8:00 am
Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
Sept 2, 2014   8:26 a.m.
Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Sept 2, 2014   6:00 a.m. 

   
 
 
 SNNLive - Amarantus  BioScience Holdings, Inc.
  Published on June 21, 2014
 
SNNLive - Amarantus BioScience Holdings, Inc.
Published on May 21, 2014

 

                                                  


      Mr. Commissiong made a presentation on Sept. 12/14 at the Aegis Capital 2014                          Healthcare and Technology Conference at web cast live at 10:00 AM PT and
               available at http://wsw.com/webcast/aegis/ambs/ .
 
    
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

           
info@vstocktransfer.com

www.VStockTransfer.com 


 
 
smiley  Amarantus anticipates launching LymPro in the fourth quarter of 2014. Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014, primarily targeting pharmaceutical clinical trials. The company does not require Clinical Laboratory Improvement Amendments (CLIA) certification to launch LymPro in the RUO market.

smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
 
 
smiley  The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects. The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.

smiley  We will not be marketing for RUO. We will be conducting business development w/ pharma customers.
 
 
   Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen” 
 
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
 
    
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 05:08:08 PM
AMBS News: Current Report Filing (8-k) 10/10/2014 04:15:12 PM
AMBS News: Current Report Filing (8-k) 10/06/2014 04:05:27 PM
AMBS News: Current Report Filing (8-k) 09/30/2014 05:13:15 PM
AMBS News: Current Report Filing (8-k) 09/24/2014 04:06:33 PM
PostSubject
#108674  Sticky Note Update from ASM Meeting: Sir Francelote 09/23/14 08:44:23 AM
#108640  Sticky Note Bascom Palmer Licenses Retinal Disorder Product to Biotech Rosym 09/21/14 06:49:48 PM
#108320  Sticky Note New or Potential investors in AMBS r00kie 09/08/14 04:02:27 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#109555   http://www.medicalnewstoday.com/releases/284196.php?tw 68-Tele 10/23/14 10:53:11 AM
#109554   I am guessing Sol has raised his pps brharris 10/23/14 10:28:04 AM
#109553   what brought on this realistic scenario? The tea joboggi 10/23/14 07:31:00 AM
#109551   I'll be buying under .073. Solantey 10/22/14 10:48:10 PM
#109546   The pps is certainly not hammering anything at joboggi 10/22/14 04:39:45 PM
#109545   Volume under 2m...Anybody with a bit of cash dsw 10/22/14 04:17:02 PM
#109544   .0984 50 day MA .0972 200 day MA. joboggi 10/22/14 01:40:22 PM
#109543   what are the details on that 153 joboggi 10/22/14 01:04:12 PM
#109542   well ,first of all, he is not talking joboggi 10/22/14 01:03:20 PM
#109541   Jason Napodano "The company is also developing an 68-Tele 10/22/14 12:57:58 PM
#109540   These are worst case scenarios that he is Toolman1890 10/22/14 10:09:29 AM
#109539   According to the agreement, Amarantus has the ability AC2 10/22/14 09:51:18 AM
#109538   You are correct. Solantey 10/22/14 09:07:00 AM
#109537   the pps of a $60 million company can joboggi 10/22/14 06:27:48 AM
#109536   @JNapodano: @Solantey $AMBS decided when they want to Toolman1890 10/21/14 09:49:40 PM
#109534   Zoom: Thank you for your response. I didn't sharpei 10/21/14 05:12:27 PM
#109533   yes, according to the longs, the pps is joboggi 10/21/14 04:40:28 PM
#109532   I have to side with Brick's reliable opinion zoomboom 10/21/14 04:21:58 PM
#109531   now, a blockbuster announcement, like a grant would joboggi 10/21/14 01:13:07 PM
#109530   the pattern means nothing unless there is confirmation. joboggi 10/21/14 12:26:04 PM
#109529   So you did say it then you didn't shamalam 10/21/14 12:18:54 PM
#109528   but there are no quotes, because there were joboggi 10/21/14 11:57:03 AM
#109525   You need to learn the difference between "Outstanding" Sccrbrg 10/20/14 09:41:37 PM
#109524   AMBS Daily 6 Month Chart. sharpei 10/20/14 09:20:40 PM
#109523   Brick: The Hammer (Yes, it was indeed sharpei 10/20/14 08:49:39 PM
#109522   I saw him say hammer also Ambs shamalam 10/20/14 07:08:35 PM
#109521   Still in the GREEN. Let's GO GO GO... hometownJOE 10/20/14 04:57:56 PM
#109520   Back to the 8's and maybe more myersvodka 10/20/14 02:25:59 PM
#109519   While the 50 MA on the weekly chart joboggi 10/20/14 02:16:29 PM
#109518   maybe the retest will finish today? I doubt joboggi 10/20/14 02:07:48 PM
#109517   I will put my accuracy rate of predictions joboggi 10/20/14 01:22:24 PM
#109516   The market was open yesteday...on Sunday? LOL you brharris 10/20/14 01:11:50 PM
#109515   Sorry that you are at or below your brickbybrick 10/20/14 01:05:37 PM
#109514   lol, you can go back and copy paste joboggi 10/20/14 01:02:54 PM
#109513   you're the only one that said the hammer brickbybrick 10/20/14 12:54:37 PM
#109512   aha, I was the only one that said joboggi 10/20/14 12:53:52 PM
#109511   nobody other than you said it was on brickbybrick 10/20/14 12:50:08 PM
#109510   I am aware of that however, well the joboggi 10/20/14 12:48:57 PM
#109509   Actually the market doesn't seem to care about brharris 10/20/14 11:39:54 AM
#109507   I'm still expecting a bottom in the .055-.06 Solantey 10/20/14 11:00:23 AM
#109506   for the umpteenth time, the hammer is on brickbybrick 10/20/14 10:59:28 AM
#109505   http://stockcharts.com/h-sc/ui?s=AMBS&p=D&yr=0&mn=1&dy=0&id=p17439596724 So, joboggi 10/20/14 10:30:06 AM
#109504   also, on the regular chart, there is no joboggi 10/20/14 09:03:47 AM
#109503   Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry brickbybrick 10/20/14 08:02:38 AM
#109502   Best to stay as a long term, you Rosym 10/20/14 07:06:52 AM
#109501   “I believe in MANF,” said Dr. Rubinfeld, “I breezy1 10/19/14 10:38:03 PM
#109500   Will need .. Unless they.. Which happened.. Please reread your post shamalam 10/19/14 10:02:48 PM
#109499   Yes, they are licensed under series 7/63 with brickbybrick 10/19/14 10:01:40 PM
#109498   To be a stock analyst and place a Solantey 10/19/14 09:57:53 PM
#109496   No, You specifically stated the company would need brickbybrick 10/19/14 09:15:29 PM
PostSubject